

07-13-06

CASE 20682D



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 731065513 US  
Express Mail Label Number

July 12, 2006  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ALESSI ET AL.

APPLICATION NO: 10/823,433

FILED: APRIL 12, 2004

FOR: FOR RAC-PK AS A THERAPEUTIC AGENT OR IN DIAGNOSTICS,  
SCREENING METHOD FOR AGENTS AND PROCESS FOR  
ACTIVATING RAC-PK

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT


Sir:

In response to the restriction requirement of March 14, 2006, Applicants hereby elect Group 1, claims 1-8, 19, 31, 32, and 34, drawn to modulators of RAC-PK activity, a RAC-PK polypeptide, pharmaceutical compositions comprising RAC-PK, its analogs, isoforms, inhibitors, or activators to regulate glycogen metabolism and/or protein synthesis, classified in class 514, subclass 2. Applicants hereby elect species (a) pharmaceutical compositions comprising RAC-PK, its analogs or isoforms and therapeutic methods of using the same. Applicants respectfully request that if the elected species is found allowable, the Examiner shall move to the next species as required by Election of species practice.

Applicant submit a petition for Three Months Extension of Time herewith, and believe that no additional fees are due with this filing. However, if it is deemed that additional fees are required, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due.

An early and favorable action on the merits is respectfully requested.

Respectfully submitted,



Mark Milstead  
Attorney for Applicant  
Reg. No. 45,825

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-4125

Date: July 12, 2006